Trial Profile

The ABNL-MARRO 001 Study: A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes.

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 21 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cedazuridine/decitabine (Primary) ; INCB 59872 (Primary) ; Itacitinib (Primary) ; Uzansertib (Primary)
Indications Myelodysplastic syndromes; Myeloproliferative disorders
Focus Adverse reactions; Therapeutic Use
Acronyms ABNL MARRO 001

Most Recent Events

12 Dec 2023 Preliminary results (n=7) of the phase 1b study presented at the 65th American Society of Hematology Annual Meeting and Exposition
24 Sep 2022 Trial design published in the BMC Cancer.
19 Dec 2021 Planned initiation date changed from 1 Dec 2021 to 1 Jan 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com